Agenus | AGEN - Assets


Agenus reported $226.8M in Assets for its fiscal quarter ending in December of 2025.





Assets Change Date
AbbVie USD 133.96B 62M Dec/2025
Agenus USD 226.8M 7.09M Dec/2025
Amgen USD 90.59B 445M Dec/2025
AstraZeneca USD 114.07B 382M Dec/2025
Bristol-Myers Squibb USD 96.89B 2.21B Sep/2025
Celldex Therapeutics USD 582.98M 65.46M Dec/2025
CSL USD 37.9B 1.5B Dec/2025
Eli Lilly USD 112.48B 2.46B Dec/2025
Gilead Sciences USD 59.02B 490M Dec/2025
GlaxoSmithKline GBP 61.12B 221M Dec/2025
Glaxosmithkline GBP 82.34B 102.25M Dec/2025
Incyte USD 6.96B 627.62M Dec/2025
Intrexon USD 73.16M 77.88M Jun/2024
J&J USD 199.21B 6.39B Dec/2025
Jiangsu Hengrui CNY 69.87B 1.54B Dec/2025
Karyopharm Therapeutics USD 96.23M 8.65M Sep/2025
MacroGenics USD 256.85M 13.92M Dec/2025
Merck EUR 51.53B 600M Dec/2025
Merck USD 129.55B 12.02B Sep/2025
Northwest Biotherapeutics USD 30.61M 1.06M Sep/2025
Novartis USD 110.95B 3.66B Dec/2025
Novavax USD 1.18B 3.38M Dec/2025
Pfizer USD 208.73B 2.64B Sep/2025
Regeneron Pharmaceuticals USD 40.56B 389.3M Dec/2025
Rigel Pharmaceuticals USD 242.53M 35.8M Sep/2025
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Veracyte USD 1.41B 38.23M Dec/2025